Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Loopia on its acquisition of .SE Direkt
Mandate

Vinge advises Loopia on its acquisition of .SE Direkt

February 11, 2019 M&A

Vinge has advised Loopia on its acquisition of the Swedish Internet Foundation’s (“IIS”) registrar business .SE Direkt.

As of mid-February, .SE Direkt's customers will have Loopia as registrar for their domains. Loopia AB, which is a part of Loopia Group, is one of Sweden's largest and fastest growing web hosting companies with operations in Sweden, Norway, and Serbia. Loopia currently has over 225,000 customers and is a market leader in Sweden within domain names and web hosting. IIS is responsible for the Swedish top-level domain .se and is an independent, business-driven and public organization who works for an internet that contributes positively to people and society.
 
Vinge’s team consisted of partners Christina Kokko (M&A) and Mikael Ståhl (Banking and Finance), and associates Linda Sengul and Martin Cronsioe (M&A), Josefine Larsson (Banking and Finance), Nicklas Thorgerzon (Commercial Agreements) and Klara Secher (IP).
 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024